Company intelligence / Profile preview

Reliance Life Sciences

Navi Mumbai, Maharashtra, Indiarellife.com ↗

Ownership: Private
Employees: ~1195
Development stage: Commercial

Overview

Reliance Life Sciences has launched five of the world’s first biosimilars and has the largest number of biosimilars in the Indian market. It also claims to have one of the highest numbers of biosimilars under development globally. The company was first to manufacture plasma proteins at scale in South Asia and has significant experience with cord blood stem cell transplants[1]. Its oncology portfolio includes several commercialized generic drugs.

Therapeutic areas: OncologyEndocrinologyRare DiseasesOtherNephrology
Modalities: Plasma proteinsbiosimilarsnovel proteinssmall molecules (oncology generics)stem cell therapies
Industry: Biotech

Drug pipeline

10 assets

ranizurel

9 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Reliance Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reliance Life Sciences.

Explore the full profile